Strikeforce: Overeem vs. Werdum Picks & Predictions
Strikeforce puts on one of its biggest events in the history of the promotion when the second half of the Strikeforce Heavyweight Grand Prix takes place from the American Airlines Arena on Saturday night at 10 p.m. ET.
Here are my picks for the four bouts that will be on the main card.
Heavyweight Grand Prix – Alistair Overeem (34-11) vs. Fabricio Werdum (14-4-1) – Overeem doesn’t have a match in this weight class in Strikeforce in my opinion. He has really beefed up and continues to have the same striking ability he has always had. Only a true wrestler has the skill set to take him out, and Werdum isn’t a wrestler. I look for Overeem to pick apart Werdum and earn a second round TKO.
Heavyweight Grand Prix – Josh Barnett (29-5) vs. Brett Rogers (11-2) – Barnett is the better fighter but Rogers does have knockout ability with one punch. Look for Barnett to play it safe early on and survive the storm from Rogers before scoring some takedowns and eventually choking out his opponent in the second round.
Lightweight Bout – K.J. Noons (10-3) vs. Jorge Masvidal (21-6) – Masvidal is tough but he hasn’t quite slugged it out with the talent that Noons has in recent years. If this is going to be a slugfest, I look for Noons to come out on top. Strikeforce would like to get Noons and Gilbert Melendez in a fight together, and I think an impressive second round KO for Noons will do just that.
Heavyweight Bout – Daniel Cormier (7-0) vs. Jeff Monson (42-11) – Cormier has had a nice little start to his MMA career, but Jeff Monson is a smart fighter that will find a way to get Cormier to the ground. Once it hits the mat, Monson will dominate the fight and eventually score a submission in the first five minutes of action.
persica in the Middle East is usually not associated with mortality severe infections with the acute respiratory syndrome and fatal infections have been reported in Israel 12 13 buy priligy generic However acquired resistance to EGFR inhibition by cetuximab has emerged as a therapeutic challenge 203